Restricted accessResearch articleFirst published online 2024-2
Cardiovascular Safety of Atomoxetine and Methylphenidate in Patients With Attention-Deficit/Hyperactivity Disorder in Japan: A Self-Controlled Case Series Study
To investigate the association between atomoxetine or methylphenidate use and arrhythmia, heart failure (HF), stroke, and myocardial infarction (MI) in attention-deficit/hyperactivity disorder (ADHD) patients mainly focused on the people of working age.
Methods:
In a self-controlled case series study using a Japanese claims database, we identified events of arrhythmia, HF, stroke, and MI among 15,472 atomoxetine new users and 12,059 methylphenidate new users. Adjusted incidence rate ratios (aIRRs) of outcome events were estimated using multivariable conditional Poisson regression.
Results:
An increased risk of arrhythmia was observed during the first 7 days after the initial atomoxetine exposure (aIRR 6.22, 95% CI [1.90, 20.35]) and in the subsequent exposure (3.23, [1.58, 6.64]). No association was found between methylphenidate exposure and arrhythmia, nor between atomoxetine or methylphenidate exposure and HF. The limited number of stroke and MI cases prevented thorough analysis.
Conclusions:
Clinicians should consider monitoring for arrhythmia after patients initiating or re-initiating atomoxetine.
AndoT.OobaN.MochizukiM.KoideD.KimuraK.LeeS. L.SetoguchiS.KubotaK. (2018). Positive predictive value of ICD-10 codes for acute myocardial infarction in Japan: A validation study at a single center. BMC Health Services Research, 18(1), 1–7. https://doi.org/10.1186/s12913-018-3727-0
2.
ChenV. C. H.YangY. H.Yu KuoT.LuM. L.TsengW. T.HouT. Y.YehJ. Y.LeeC. T. C.ChenY. L.LeeM. J.DeweyM. E.GossopM. (2020). Methylphenidate and the risk of burn injury among children with attention-deficit/hyperactivity disorder. Epidemiology and Psychiatric Sciences, 29, e146. https://doi.org/10.1017/S2045796020000608
3.
CoghillD.BanaschewskiT.CorteseS.AshersonP.BrandeisD.BuitelaarJ.DaleyD.DanckaertsM.DittmannR. W.DoepfnerM.FerrinM.HollisC.HoltmannM.ParamalaS.Sonuga-BarkeE.SoutulloC.SteinhausenH. C.van der OordS.WongI. C. K.. . . SimonoffE. (2023). The management of ADHD in children and adolescents: Bringing evidence to the clinic: Perspective from the European ADHD Guidelines Group (EAGG). European Child and Adolescent Psychiatry, 32(8), 1337–1361. https://doi.org/10.1007/s00787-021-01871-x
4.
CooperW. O.HabelL. A.SoxC. M.ChanK. A.ArbogastP. G.CheethamT. C.MurrayK. T.QuinnV. P.SteinC. M.CallahanS. T.FiremanB. H.FishF. A.KirshnerH. S.O’DuffyA.ConnellF. A.RayW. A. (2011). ADHD drugs and serious cardiovascular events in children and young adults. New England Journal of Medicine, 365(20), 1896–1904. https://doi.org/10.1056/NEJMoa1110212
FujiharaK.Yamada-HaradaM.MatsubayashiY.KitazawaM.YamamotoM.YaguchiY.SeidaH.KodamaS.AkazawaK.SoneH. (2021). Accuracy of Japanese claims data in identifying diabetes-related complications. Pharmacoepidemiology and Drug Safety, 30(5), 594–601. https://doi.org/10.1002/pds.5213
7.
FukasawaT.TakahashiH.TakahashiK.TanemuraN.AmagaiM.UrushiharaH. (2021). Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with anticonvulsants in a Japanese population: Matched case–control and cohort studies. Allergology International, 70(3), 335–342. https://doi.org/10.1016/j.alit.2021.01.004
8.
FukasawaT.UrushiharaH.TakahashiH.OkuraT.KawakamiK. (2023). Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with antibiotic use: A case-crossover study. The Journal of Allergy and Clinical Immunology: In Practice. Advance online publication. https://doi.org/10.1016/j.jaip.2023.07.012
9.
HabelL. A.CooperW. O.SoxC. M.ChanK. A.FiremanB. H.ArbogastP. G.CheethamT. C.QuinnV. P.DublinS.BoudreauD. M.AndradeS. E.PawloskiP. A.RaebelM. A.SmithD. H.AchacosoN.UratsuC.GoA. S.SidneyS.Nguyen-HuynhM. N.. . . SelbyJ. V. (2011). ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA, 306(24), 2673–2683. https://doi.org/10.1001/jama.2011.1830
10.
HennissenL.BakkerM. J.BanaschewskiT.CarucciS.CoghillD.DanckaertsM.DittmannR. W.HollisC.KovshoffH.McCarthyS.NagyP.Sonuga-BarkeE.WongI. C. K.ZuddasA.RosenthalE.BuitelaarJ. K. (2017). Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: A systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs, 31(3), 199–215. https://doi.org/10.1007/s40263-017-0410-7
11.
HoughtonR.de VriesF.LossG. (2020). Psychostimulants/atomoxetine and serious cardiovascular events in children with ADHD or autism spectrum disorder. CNS Drugs, 34(1), 93–101. https://doi.org/10.1007/s40263-019-00686-4
12.
ImagawaH.NagarS. P.MontgomeryW.NakamuraT.SatoM.DavisK. L. (2018). Treatment patterns, health care resource utilization, and costs in Japanese adults with attention-deficit hyperactivity disorder treated with atomoxetine. Neuropsychiatric Disease and Treatment, 14, 611–621. https://doi.org/10.2147/NDT.S150261
13.
IwagamiMasaoTakeuchiY. (2021). Introduction to self-controlled study design. Annals of Clinical Epidemiology, 3(3), 67–73.
JeongH. E.LeeH.LaiE. C. C.LiaoT. C.ManK. K. C.WongI. C. K.CoghillD.ChiM. H.HsiehC. Y.ShinJ. Y. (2021). Association between methylphenidate and risk of myocardial infarction: A multinational self-controlled case series study. Pharmacoepidemiology and Drug Safety, 30(10), 1458–1467. https://doi.org/10.1002/pds.5322
16.
KikuchiD.ObaraT.TokunagaM.ShiozawaM.TakahashiA.ItoM.HinoH.MiuraR.HayakawaS.WatanabeY. (2021). Drug prescription for attention deficit hyperactivity disorder drugs in pediatric outpatients: A retrospective survey of Japanese administrative data (2012–2018). Asian Journal of Psychiatry, 57, 102512. https://doi.org/10.1016/j.ajp.2020.102512
17.
LanganS. M.SchmidtS. A.WingK.EhrensteinV.NichollsS. G.FilionK. B.KlungelO.PetersenI.SorensenH. T.DixonW. G.GuttmannA.HarronK.HemkensL. G.MoherD.SchneeweissS.SmeethL.SturkenboomM.von ElmE.WangS. V.BenchimolE. I. (2018). The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). The BMJ, 363, k3532. https://doi.org/10.1136/bmj.k3532
18.
LiangE. F.LimS. Z.TamW. W.HoC. S.ZhangM. W.McIntyreR. S.HoR. C. (2018). The effect of methylphenidate and atomoxetine on heart rate and systolic blood pressure in young people and adults with attention-deficit hyperactivity disorder (ADHD): Systematic review, meta-analysis, and meta-regression. International Journal of Environmental Research and Public Health, 15(8), 1789. https://doi.org/10.3390/ijerph15081789
19.
LiuH.FengW.ZhangD. (2019). Association of ADHD medications with the risk of cardiovascular diseases: A meta-analysis. European Child and Adolescent Psychiatry, 28(10), 1283–1293. https://doi.org/10.1007/s00787-018-1217-x
20.
ManK. K. C.LauW. C. Y.CoghillD.BesagF. M. C.CrossJ. H.IpP.WongI. C. K. (2020). Association between methylphenidate treatment and risk of seizure: A population-based, self-controlled case-series study. The Lancet Child and Adolescent Health, 4(6), 435–443. https://doi.org/10.1016/S2352-4642(20)30100-0
21.
MasudaS.FukasawaT.TakeuchiM.FujibayashiS.OtsukiB.MurataK.ShimizuT.MatsudaS.KawakamiK. (2023). Reoperation rates of microendoscopic discectomy compared with conventional open lumbar discectomy: A large-database study. Clinical Orthopaedics and Related Research, 481(1), 145–154. https://doi.org/10.1097/CORR.0000000000002322
NagaiK.TanakaT.KodairaN.KimuraS.TakahashiY.NakayamaT. (2021). Data resource profile: JMDC claims database sourced from health insurance societies. Journal of General and Family Medicine, 22(3), 118–127. https://doi.org/10.1002/jgf2.422
24.
NICE. (2018). National Institute for Health and Care Excellence Attention deficit hyperactivity disorder: Diagnosis and management. https://doi.org/10.1002/pnp.511
25.
OkumuraY.UsamiM.OkadaT.SaitoT.NegoroH.TsujiiN.FujitaJ.IidaJ. (2019). Prevalence, incidence and persistence of ADHD drug use in Japan. Epidemiology and Psychiatric Sciences, 28(6), 692–696. https://doi.org/10.1017/S2045796018000252
26.
OnoY.TanedaY.TakeshimaT.IwasakiK.YasuiA. (2020). Validity of claims diagnosis codes for cardiovascular diseases in diabetes patients in Japanese administrative database. Clinical Epidemiology, 12, 367–375. https://doi.org/10.2147/CLEP.S245555
27.
PageR. L.O’bryantC. L.ChengD.DowT. J.KyB.SteinC. M.SpencerA. P.TruppR. J.LindenfeldJ. A. (2016). Drugs that may cause or exacerbate heart failure. Circulation, 134(6), e32–e69. https://doi.org/10.1161/CIR.0000000000000426
28.
PetersenI.DouglasI.WhitakerH. (2016). Self controlled case series methods: An alternative to standard epidemiological study designs. The BMJ, 354, i4515. https://doi.org/10.1136/bmj.i4515
RamanS. R.MarshallS. W.HaynesK.GaynesB. N.NaftelA. J.StürmerT. (2013). Stimulant treatment and injury among children with attention deficit hyperactivity disorder: An application of the self-controlled case series study design. Injury Prevention, 19(3), 164–170. https://doi.org/10.1136/injuryprev-2012-040483
31.
SchellemanH.BilkerW. B.StromB. L.KimmelS. E.NewcombC.GuevaraJ. P.DanielG. W.CzirakyM. J.HennessyS. (2011). Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics, 127(6), 1102–1110. https://doi.org/10.1542/peds.2010-3371
32.
ShinJ. Y.RougheadE. E.ParkB. J.PrattN. L. (2016). Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): Nationwide self controlled case series study. The BMJ, 353, i2550. https://doi.org/10.1136/bmj.i2550
33.
SongP.ZhaM.YangQ.ZhangY.LiX.RudanI. (2021). The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis. Journal of Global Health, 11, 1–9. https://doi.org/10.7189/jogh.11.04009
34.
TadrousM.ShakeriA.ChuC.WattJ.MamdaniM. M.JuurlinkD. N.GomesT. (2021). Assessment of stimulant use and cardiovascular event risks among older adults. JAMA Network Open, 4(10), 1–13. https://doi.org/10.1001/jamanetworkopen.2021.30795
35.
ThomasR.SandersS.DoustJ.BellerE.GlasziouP. (2015). Prevalence of attention-deficit/hyperactivity disorder: A systematic review and meta-analysis. Pediatrics, 135(4), e994–e1001. https://doi.org/10.1542/peds.2014-3482
36.
TisdaleJ. E.ChungM. K.CampbellK. B.HammadahM.JoglarJ. A.LeclercJ.RajagopalanB. (2020). Drug-induced arrhythmias: A scientific statement from the american heart association. Circulation, 142, E214–E233. https://doi.org/10.1161/CIR.0000000000000905
37.
TownsendL.WalkupJ. T.CrystalS.OlfsonM. (2012). A systematic review of validated methods for identifying depression using administrative data. Pharmacoepidemiology and Drug Safety, 21, 163–173. https://doi.org/10.1002/pds.2310
38.
TuranaY.TengkawanJ.ChiaY. C.NathanielM.WangJ. G.SukonthasarnA.ChenC. H.MinhH.van, BuranakitjaroenP.ShinJ.SiddiqueS.NailesJ. M.ParkS.TeoB. W.SisonJ.Ann SoenartaA.HoshideS.TayJ. C.Prasad SogunuruG.. . . KarioK. (2021). Hypertension and stroke in Asia: A comprehensive review from HOPE Asia. Journal of Clinical Hypertension, 23(3), 513–521. https://doi.org/10.1111/jch.14099
39.
WintersteinA. G.GerhardT.KubilisP.SaidiA.LindenS.CrystalS.ZitoJ.ShusterJ. J.OlfsonM. (2012). Cardiovascular safety of central nervous system stimulants in children and adolescents: Population based cohort study. The BMJ, 345(7869), 1–12. https://doi.org/10.1136/bmj.e4627
40.
WolraichM. L.HaganJ. F.AllanC.ChanE.DavisonD.EarlsM.EvansS. W.FlinnS. K.FroehlichT.FrostJ.HolbrookJ. R.LehmannC. U.LessinH. R.OkechukwuK.PierceK. L.WinnerJ. D.ZurhellenW. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 144(4), e20192528. https://doi.org/10.1542/peds.2019-2528
41.
YoshidaM.ObaraT.KikuchiS.SatohM.MorikawaY.OobaN.YamaguchiH.ManoN. (2020). Drug prescriptions for children with ADHD in Japan: A study based on health insurance claims data between 2005 and 2015. Journal of Attention Disorders, 24(2), 175–191. https://doi.org/10.1177/1087054719843179
42.
YoshidaS.TakeuchiM.Tanaka-MizunoS.MizunoK.NakashimaM.FukasawaT.KawakamiK. (2022). Clinical epidemiology and pharmacoepidemiology studies with real-world databases. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 98(10), 517–528. https://doi.org/10.2183/pjab.98.026
43.
ZhangL.YaoH.LiL.RietzE.du, AndellP.Garcia-argibayM.OnofrioB. M. D. (2022). Risk of cardiovascular diseases associated with medications used in attention-deficit/hyperactivity disorder a systematic review and meta-analysis. JAMA Network Open, 5(11), e2243597. https://doi.org/10.1001/jamanetworkopen.2022.43597
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
